Trial reportTranslational psychiatry2021
Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study.
Trial report in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 56 citations in OpenAlex.
- Spectral Changes of EEG Following a 6-Week Low-Dose Oral Ketamine Treatment in Adults With Major Depressive Disorder and Chronic Suicidality.The international journal of neuropsychopharmacology · 2023Trial
- Efficacy of Oral Ketamine in Patients with Depression and Suicidality: A Retrospective Study.Indian journal of psychological medicine · 2026Article
- A Novel Tertiary Carbamate Prodrug Strategy to Overcome Metabolic Barriers in Oral Ketamine Delivery.ChemMedChem · 2026Article
- Thinking About Suicide for a Long Time: A Scoping Review of Empirical Studies on Persistent Suicidal Ideation.Suicide & life-threatening behavior · 2025Article
- Black tea as a possible vehicle for administration of oral ketamine.Indian journal of psychiatry · 2025Article
- Oral ketamine effects on dynamics of functional network connectivity in patients treated for chronic suicidality.European archives of psychiatry and clinical neuroscience · 2025Article
- A Preliminary Approach to Oral Low-Dose Ketamine Self-Administration in Mice (Current issues in molecular biology · 2025Article
- Resting-State Electroencephalogram Complexity Is Associated With Oral Ketamine Treatment Response: A Bayesian Analysis of Lempel-Ziv Complexity and Multiscale Entropy.Brain and behavior · 2024Article
- Oral ketamine may offer a solution to the ketamine conundrum.Psychopharmacology · 2023Review
- Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2023Review
- Review
- Dynamic regulation of the extracellular matrix in reward memory processes: a question of time.Frontiers in cellular neuroscience · 2023Review
- Ketamine study: Protocol for naturalistic prospective multicenter study on subcutaneous ketamine infusion in depressed patients with active suicidal ideation.Frontiers in psychiatry · 2023Article
- A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression.Clinical case reports · 2022Article
- A Pilot Study of Ketamine Infusion after Suicide Attempt: New Frontiers in Treating Acute Suicidality in a Real-World Medical Setting.International journal of environmental research and public health · 2022Article
- Suicide versus Accidental Death by Autoerotic Asphyxiation in a Patient Receiving Intravenous Ketamine for Depression.Case reports in psychiatry · 2022Article
- (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy.Chronic stress (Thousand Oaks, Calif.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, low-dose ketamine has been proposed as a rapid-acting treatment option for suicidality. The majority of studies to date have utilised intravenous (IV) ketamine, however, this route of administration has limitations. On the other hand, oral ketamine can be administered in a range of settings, which is important in treating suicidality, although studies as to safety and feasibility are lacking. n = 32 adults (aged 22-72 years; 53% female) with chronic suicidal thoughts participated in the Oral Ketamine Trial on Suicidality (OKTOS), an open-label trial of sub-anaesthetic doses of oral ketamine over 6 weeks. Participants commenced with 0.5 mg/kg of ketamine, which was titrated to a maximum 3.0 mg/kg. Follow-up assessments occurred at 4 weeks after the final dose. The primary outcome measure was the Beck Scale for Suicide Ideation (BSS) and secondary measures included scales for suicidality and depressive symptoms, and measures of functioning and well-being. Mean BSS scores significantly reduced from a high level of suicidal ideation at the pre-ketamine (week 0) timepoint to below the clinical threshold at the post-ketamine (week 6) timepoint. The proportion of participants that achieved clinical improvement within the first 6 weeks was 69%, whereas 50% achieved a significant improvement by the follow-up (week 10) timepoint. Six weeks of oral ketamine treatment in participants with chronic suicidality led to significant reduction in suicidal ideation. The response observed in this study is consistent with IV ketamine trials, suggesting that oral administration is a feasible and tolerable alternative treatment for chronic suicidality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.